Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.

Winer BY, Shirvani-Dastgerdi E, Bram Y, Sellau J, Low BE, Johnson H, Huang T, Hrebikova G, Heller B, Sharon Y, Giersch K, Gerges S, Seneca K, Pais MA, Frankel AS, Chiriboga L, Cullen J, Nahass RG, Lutgehetmann M, Toettcher JE, Wiles MV, Schwartz RE, Ploss A.

Sci Transl Med. 2018 Jun 27;10(447). pii: eaap9328. doi: 10.1126/scitranslmed.aap9328.

PMID:
29950446
2.

Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.

Giersch K, Bhadra OD, Volz T, Allweiss L, Riecken K, Fehse B, Lohse AW, Petersen J, Sureau C, Urban S, Dandri M, Lütgehetmann M.

Gut. 2019 Jan;68(1):150-157. doi: 10.1136/gutjnl-2017-314713. Epub 2017 Dec 7.

PMID:
29217749
3.

Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice.

Giersch K, Homs M, Volz T, Helbig M, Allweiss L, Lohse AW, Petersen J, Buti M, Pollicino T, Sureau C, Dandri M, Lütgehetmann M.

Sci Rep. 2017 Jun 16;7(1):3757. doi: 10.1038/s41598-017-03946-9.

4.

Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.

Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, Lohse AW, Beninati C, Pollicino T, Urban S, Lütgehetmann M, Dandri M.

Gut. 2018 Mar;67(3):542-552. doi: 10.1136/gutjnl-2016-312162. Epub 2017 Apr 20.

PMID:
28428345
5.

Serum HBV pgRNA as a clinical marker for cccDNA activity.

Giersch K, Allweiss L, Volz T, Dandri M, Lütgehetmann M.

J Hepatol. 2017 Feb;66(2):460-462. doi: 10.1016/j.jhep.2016.09.028. Epub 2016 Nov 5. No abstract available.

PMID:
27826059
6.

Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation.

Allweiss L, Gass S, Giersch K, Groth A, Kah J, Volz T, Rapp G, Schöbel A, Lohse AW, Polywka S, Pischke S, Herker E, Dandri M, Lütgehetmann M.

J Hepatol. 2016 May;64(5):1033-1040. doi: 10.1016/j.jhep.2016.01.011. Epub 2016 Jan 22.

PMID:
26805671
7.

Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte.

Giersch K, Dandri M.

J Clin Transl Hepatol. 2015 Sep 28;3(3):220-9. doi: 10.14218/JCTH.2015.00018. Epub 2015 Sep 15. Review.

8.

Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection.

Giersch K, Allweiss L, Volz T, Helbig M, Bierwolf J, Lohse AW, Pollok JM, Petersen J, Dandri M, Lütgehetmann M.

J Hepatol. 2015 Aug;63(2):346-53. doi: 10.1016/j.jhep.2015.03.011. Epub 2015 Mar 17.

PMID:
25795587
9.

Relevance of a full-length genomic RNA standard and a thermal-shock step for optimal hepatitis delta virus quantification.

Homs M, Giersch K, Blasi M, Lütgehetmann M, Buti M, Esteban R, Dandri M, Rodriguez-Frias F.

J Clin Microbiol. 2014 Sep;52(9):3334-8. doi: 10.1128/JCM.00940-14. Epub 2014 Jul 2.

10.

Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism.

Oehler N, Volz T, Bhadra OD, Kah J, Allweiss L, Giersch K, Bierwolf J, Riecken K, Pollok JM, Lohse AW, Fehse B, Petersen J, Urban S, Lütgehetmann M, Heeren J, Dandri M.

Hepatology. 2014 Nov;60(5):1483-93. doi: 10.1002/hep.27159. Epub 2014 May 19.

PMID:
24711282
11.

Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration.

Allweiss L, Volz T, Lütgehetmann M, Giersch K, Bornscheuer T, Lohse AW, Petersen J, Ma H, Klumpp K, Fletcher SP, Dandri M.

J Hepatol. 2014 Mar;60(3):500-7. doi: 10.1016/j.jhep.2013.10.021. Epub 2013 Oct 26.

PMID:
24398036
12.

Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection.

Giersch K, Helbig M, Volz T, Allweiss L, Mancke LV, Lohse AW, Polywka S, Pollok JM, Petersen J, Taylor J, Dandri M, Lütgehetmann M.

J Hepatol. 2014 Mar;60(3):538-44. doi: 10.1016/j.jhep.2013.11.010. Epub 2013 Nov 23.

PMID:
24280293
13.

Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery.

Miehlke RK, Schneider S, Sörgel F, Muth P, Henschke F, Giersch KH, Münzel P.

Drugs. 1990;40 Suppl 5:57-61.

PMID:
2081495
14.

Efficacy and safety of nabumetone in patients with rheumatic diseases. Results of an outpatient study involving 8,865 patients.

Stroehmann I, Giersch KH, Zeidler H, Münzel P.

Drugs. 1990;40 Suppl 5:50-2. No abstract available.

PMID:
2081493
15.

[Transdermal therapy of stable angina pectoris. Comparison of 2 different transdermal systems].

Kramar M, Giersch KH, Schneider HT.

Fortschr Med. 1987 Jun 10;105(17):340-2. German. No abstract available.

PMID:
3111961

Supplemental Content

Loading ...
Support Center